NVP-BAW2881
|
|
|
- CAS-Nr.
- 861875-60-7
- Englisch Name:
- NVP-BAW2881
- Synonyma:
- CS-2238;BAW2881;NVP-BAW2881;NVP-BAW2881 (BAW2881;BAW2881 (NVP-BAW2881);NVP-BAW2881, 10 mM in DMSO;BAW2881 (NVP-BAW2881) ，S8189;NVP-BAW2881;NVP-BAW-2881;;NVP-BAW 2881;6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide;1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-
- CBNumber:
- CB93133229
- Summenformel:
- C22H15F3N4O2
- Molgewicht:
- 424.38
- MOL-Datei:
- 861875-60-7.mol
|
NVP-BAW2881 Eigenschaften
- storage temp.
- Store at -20°C
- L?slichkeit
- ≥42.4 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
- Aggregatzustand
- solid
- Farbe
- White to off-white
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
NVP-BAW2881 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
BAW 2881 is a vascular endothelial growth factor receptor (VEGFR) inhibitor (IC
50s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively). It inhibits Tie2 and RET with IC
50 values of 0.65 and 0.41 μM, respectively, but demonstrates IC
50 values great than 10 μM toward a large panel of additional kinases. BAW 2881 was shown to block VEGF-A-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells and lymphatic endothelial cells
in vitro. In a mouse model of psoriasis, both oral and topical administration of BAW 2881 reduced psoriasis-like inflammation in ear skin. Topical application of BAW 2881 also reduced VEGF-A-induced vascular permeability and inhibited contact hypersensitivity reactions and UV-B-induced erythema in the skin of domestic pigs.
NVP-BAW2881 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
NVP-BAW2881 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 90)Lieferanten
- NVP-BAW2881
- BAW2881
- BAW2881 (NVP-BAW2881)
- 6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide
- 6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid (3-trifluoromethyl phenyl)amide
- CS-2238
- NVP-BAW2881;NVP-BAW-2881;;NVP-BAW 2881
- 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-
- NVPBAW2881,inhibit,BAW 2881,NVP BAW2881,Vascular endothelial growth factor receptor,VEGFR,Inhibitor,NVP-BAW2881,BAW-2881,NVP-BAW-2881
- NVP-BAW2881, 10 mM in DMSO
- NVP-BAW2881 (BAW2881
- BAW2881 (NVP-BAW2881) ，S8189
- 861875-60-7
